Trial Profile
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Sitafloxacin (Primary) ; Ertapenem
- Indications Gram-negative infections; Urinary tract infections
- Focus Therapeutic Use
- 07 Mar 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 07 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 07 Mar 2023 Status changed from recruiting to active, no longer recruiting.